Read by QxMD icon Read

Proton beam therapy

Rosanna Yeung, Stephen R Bowen, Tobias R Chapman, Grayden T MacLennan, Smith Apisarnthanarax
PURPOSE: Normal liver-sparing with proton beam therapy (PBT) allows for dose escalation in the treatment of liver malignancies, but it may result in high doses to the chest wall (CW). CW toxicity (CWT) data after PBT for liver malignancies are limited, with most published reports describing toxicity after a combination of hypofractionated proton and photon radiation therapy. We examined the incidence and associated factors for CWT after hypofractionated PBT for liver malignancies. METHODS AND MATERIALS: We retrospectively reviewed the charts of 37 consecutive patients with liver malignancies (30 hepatocellular carcinoma, 6 intrahepatic cholangiocarcinoma, and 1 metastasis) treated with hypofractionated PBT...
December 24, 2017: Practical Radiation Oncology
T Mee, N F Kirkby, K J Kirkby
Proton beam therapy (PBT) is still relatively new in cancer treatment and the clinical evidence base is relatively sparse. Mathematical modelling offers assistance when selecting patients for PBT and predicting the demand for service. Discrete event simulation, normal tissue complication probability, quality-adjusted life-years and Markov Chain models are all mathematical and statistical modelling techniques currently used but none is dominant. As new evidence and outcome data become available from PBT, comprehensive models will emerge that are less dependent on the specific technologies of radiotherapy planning and delivery...
February 13, 2018: Clinical Oncology: a Journal of the Royal College of Radiologists
Fahed Alsanea, Francois Therriault-Proulx, Gabriel Sawakuchi, Sam Beddar
PURPOSE: Currently, no detectors are capable of simultaneously measuring dose and linear energy transfer (LET) in real time. In this study, we evaluated the feasibility of exploiting the difference in the response of various organic plastic scintillation detectors to measure LET and dose in therapeutic proton beams. The hypothesis behind this work was that the ratio of the responses of different scintillators exposed to the same proton beam can be used to obtain a LET-vs-ratio calibration curve that can then be used to infer LET under any other measurement conditions...
February 15, 2018: Medical Physics
Carolina Rabin, Marcello Gomes Gonçalves, Sergio Barbosa Duarte, Gabriel Gonzalez Sprinberg
Radiation treatments of cancer have evolved to include massive particle beams, instead of traditional irradiation procedures. Thus patient doses and workers radiological protection became issues of constant concern for these new technologies, especially for proton- and heavy-ion-therapy. In beam energies of interest of heavy-ion-therapy, secondary particle radiation comes from proton, neutron and neutral and charged pions produced in the nuclear collisions of the beam with human tissue atoms. This work, for the first time, offers the upper bound of meson radiation dose in organic tissues due to secondary meson radiation in heavy-ion therapy...
February 14, 2018: Journal of Radiological Protection: Official Journal of the Society for Radiological Protection
M Gao, M M Mohiuddin, W F Hartsell, M Pankuch
PURPOSE: GRID therapy is an effective treatment for bulky tumors. Linear accelerator (Linac)-produced photon beams collimated through blocks or multi-leaf collimators (MLCs) are the most common methods used to deliver this therapy. Utilizing the newest proton delivery method of pencil beam scanning (PBS) can further improve the efficacy of GRID therapy. In this study, we developed a method of delivering GRID therapy using proton PBS, evaluated the dosimetry of this novel technique and applied this method in two clinical cases...
February 12, 2018: Medical Physics
Tobias R Chapman, Stephen R Bowen, Stephanie K Schaub, Rosanna H Yeung, Sharon W Kwan, James O Park, Lei Yu, William P Harris, Guy E Johnson, Iris W Liou, Matthew J Nyflot, Smith Apisarnthanarax
BACKGROUND: Our purpose was to define the most clinically relevant "nonclassic" radiation-induced liver disease (RILD) endpoints in cirrhotic patients receiving stereotactic body radiation therapy or proton beam therapy for primary liver cancer. METHODS AND MATERIALS: We retrospectively collected pretreatment, detailed toxicity (≤6 months posttreatment), and outcomes data from 48 patients. Deaths were examined for association with RILD. Univariate and multivariate Cox models defined significant predictors of overall survival (OS)/RILD-specific survival (RILD-SS)...
November 4, 2017: Practical Radiation Oncology
Yasuhiro Hirano, Masakatsu Onozawa, Hidehiro Hojo, Atsushi Motegi, Sadatomo Zenda, Kenji Hotta, Shunsuke Moriya, Hidenobu Tachibana, Naoki Nakamura, Takashi Kojima, Tetsuo Akimoto
BACKGROUND: The purpose of this study was to perform a dosimetric comparison between proton beam therapy (PBT) and photon radiation therapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who were treated with PBT in our institution. In addition, we evaluated the correlation between toxicities and dosimetric parameters, especially the doses to normal lung or heart tissue, to clarify the clinical advantage of PBT over photon radiation therapy. METHODS: A total of 37 consecutive patients with Stage III thoracic ESCC who had received PBT with or without concurrent chemotherapy between October 2012 and December 2015 were evaluated in this study...
February 9, 2018: Radiation Oncology
Tae Hyun Kim, Joong-Won Park, Bo Hyun Kim, Dae Yong Kim, Sung Ho Moon, Sang Soo Kim, Ju Hee Lee, Sang Myung Woo, Young-Hwan Koh, Woo Jin Lee, Chang-Min Kim
Objective: To evaluate the optimal time of tumour response and effectiveness of hypofractionated proton beam therapy (PBT) for hepatocellular carcinoma (HCC). Results: Overall, treatment was well tolerated with no grade toxicity ≥3. Of 71 patients, 66 patients (93%) eventually reached complete response (CR) after PBT: 93.9% (62 of 66) of patients who reached CR within 12 months, and the remaining 4 patients (6.1%) reached CR at 12.5, 16.2, 19.1 and 21.7 months, respectively...
January 9, 2018: Oncotarget
Han-Back Shin, Moo-Sub Kim, Sunmi Kim, Kyu Bom Kim, Joo-Young Jung, Do-Kun Yoon, Tae Suk Suh
The purpose of this study is to evaluate the prompt gamma ray imaging technique according to the clinical boron concentration range during proton boron fusion therapy (PBFT). To acquire a prompt gamma ray image from 32 projections, we simulated four head single photon emission computed tomography and a proton beam nozzle using a Monte Carlo simulation. We used modified ordered subset expectation maximization reconstruction algorithm with a graphic processing unit for fast image acquisition. Boron concentration was set as 20 to 100 μg at intervals of 20 μg...
January 9, 2018: Oncotarget
Juliette Thariat, Jean Louis Habrand, Paul Lesueur, Abdulhamid Chaikh, Emmanuel Kammerer, Delphine Lecomte, Alain Batalla, Jacques Balosso, Thomas Tessonnier
Proton therapy is a radiotherapy, based on the use of protons, charged subatomic particles that stop at a given depth depending on their initial energy (pristine Bragg peak), avoiding any output beam, unlike the photons used in most of the other modalities of radiotherapy. Proton therapy has been used for 60 years, but has only become ubiquitous in the last decade because of recent major advances in particle accelerator technology. This article reviews the history of clinical implementation of protons, the nature of the technological advances that now allows its expansion at a lower cost...
February 5, 2018: Bulletin du Cancer
Gonzalez Torres Maria Jose, Henniger Jürgen
In order to expand the Monte Carlo transport program AMOS to particle therapy applications, the ion module is being developed in the radiation physics group (ASP) at the TU Dresden. This module simulates the three main interactions of ions in matter for the therapy energy range: elastic scattering, inelastic collisions and nuclear reactions. The simulation of the elastic scattering is based on the Binary Collision Approximation and the inelastic collisions on the Bethe-Bloch theory. The nuclear reactions, which are the focus of the module, are implemented according to a probabilistic-based model developed in the group...
January 2018: Physica Medica: PM
C Panaino, M J Taylor, R MacKay, M J Merchant, T Price, B Pheonix, S Green
In proton beam therapy precise knowledge of the proton beam range is essential to guarantee the treatment's efficacy and to avoid unnecessary toxicities. Unlike photon beams, protons stop inside the patient's body, therefore a direct detection of the distal fall-off is impossible. One technique to determine the beam range is to detect the prompt gamma (PG) rays emitted from the nuclei de-exciting following proton bombardment [1]. PG emission is almost instantaneous and has a high-production rate. The aim of this project is to develop a new method, based on an optimized PG detector system, which can achieve 3D range determination with an uncertainty of no more than 2 mm...
January 2018: Physica Medica: PM
Michelle S Gentile, Beow Y Yeap, Harald Paganetti, Claire P Goebel, Dillon E Gaudet, Sara L Gallotto, Elizabeth A Weyman, Michael L Morgan, Shannon M MacDonald, Drosoula Giantsoudi, Judith Adams, Nancy J Tarbell, Hanne Kooy, Torunn I Yock
PURPOSE: Proton radiation therapy is commonly used in young children with brain tumors for its potential to reduce late effects. However, some proton series report higher rates of brainstem injury (0%-16%) than most photon series (2.2%-8.6%). We report the incidence of brainstem injury and a risk factor analysis in pediatric patients with posterior fossa primary tumors treated with proton radiation therapy at our institution. METHODS AND MATERIALS: The study included 216 consecutive patients treated between 2000 and 2015...
March 1, 2018: International Journal of Radiation Oncology, Biology, Physics
Chenyang Shen, Bin Li, Liyuan Chen, Ming Yang, Yifei Lou, Xun Jia
PURPOSE: Accurate calculation of proton stopping power ratio (SPR) relative to water is crucial to proton therapy treatment planning, since SPR affects prediction of beam range. Current standard practice derives SPR using a single CT scan. Recent studies showed that dual-energy CT (DECT) offers advantages to accurately determine SPR. One method to further improve accuracy is to incorporate prior knowledge on human tissue composition through a dictionary approach. In addition, it is also suggested that using CT images with multiple (more than two) energy channels, i...
February 5, 2018: Medical Physics
Christopher Salvatore Graffeo, Avital Perry, Michael J Link, David J Daniels
Pediatric craniopharyngioma is a rare sellar-region epithelial tumor that, in spite of its typically benign pathology, has the potential to be clinically devastating, and presents a host of formidable management challenges for the skull base surgeon. Strategies in craniopharyngioma care have been the cause of considerable controversy, with respect to both philosophical and technical issues. Key questions remain unresolved, and include optimizing extent-of-resection goals; the ideal radiation modality and its role as an alternative, adjuvant, or salvage treatment; appropriate indications for expanded endoscopic endonasal surgery as an alternative to transcranial microsurgery; risks and benefits of skull base techniques in a pediatric population; benefits of and indications for intracavitary therapies; and the preferred management of common treatment complications...
February 2018: Journal of Neurological Surgery. Part B, Skull Base
E R Gatfield, D J Noble, G C Barnett, N Y Early, A C F Hoole, N F Kirkby, S J Jefferies, N G Burnet
AIMS: To evaluate the long-term outcomes of patients with chordoma and low-grade chondrosarcoma after surgery and high-dose radiotherapy. MATERIALS AND METHODS: High-dose photon radiotherapy was delivered to 28 patients at the Neuro-oncology Unit at Addenbrooke's Hospital (Cambridge, UK) between 1996 and 2016. Twenty-four patients were treated with curative intent, 17 with chordoma, seven with low-grade chondrosarcoma, with a median dose of 65 Gy (range 65-70 Gy)...
February 2, 2018: Clinical Oncology: a Journal of the Royal College of Radiologists
Takashi Ono, Tatsuya Nakamura, Hisashi Yamaguchi, Yusuke Azami, Kanako Takayama, Motohisa Suzuki, Hitoshi Wada, Yasuhiro Kikuchi, Masao Murakami, Kenji Nemoto
BACKGROUND: The purpose of the present study was to evaluate retrospectively the efficacy and safety of proton beam therapy for elderly patients (≥80 years of age) with non-small cell lung cancer. METHODS: Patients diagnosed with T1-4 N0 M0 non-small cell lung cancer and treated with proton beam therapy between January 2009 and 2015 were recruited from our database retrospectively. Toxicity was evaluated using The Common Terminology Criteria for Adverse Events version 4...
February 5, 2018: Radiation Oncology
Xiufang Tian, Kun Liu, Yong Hou, Jian Cheng, Jiandong Zhang
Proton beam therapy (PBT) has been increasingly used in a variety of cancers due to its excellent physical properties and superior dosimetric parameters. PBT may improve patient survival by improving the local tumor treatment rate while reducing injury to normal organs, which may result in fewer radiation-induced adverse effects. However, the significant cost of establishing and maintaining proton facilities cannot be overlooked. In addition, there has been significant controversy regarding routine application of this treatment in certain types of cancer...
January 2018: Molecular and Clinical Oncology
Hyun Mi Kim, Suk Hee Kim, Bo Sun Kang
BACKGROUND/OBJECTIVES: Exposure of the normal lung tissue around the cancerous tumor during radiotherapy causes serious side effects such as pneumonitis and pulmonary fibrosis. Radioprotectors used during cancer radiotherapy could protect the patient from side effects induced by radiation injury of the normal tissue. Delphinidin has strong antioxidant properties, and it works as the driving force of a radioprotective effect by scavenging radiation-induced reactive oxygen species (ROS)...
February 2018: Nutrition Research and Practice
Masahide Matsuda, Hidehiro Kohzuki, Eiichi Ishikawa, Tetsuya Yamamoto, Hiroyoshi Akutsu, Shingo Takano, Masashi Mizumoto, Koji Tsuboi, Akira Matsumura
Despite cumulative evidence supporting the idea that gross total resection (GTR) contributes to prolonged survival of patients with glioblastoma (GBM), the survival outcome of such patients remains unsatisfactory. To develop more effective postoperative therapeutic strategies for patients who underwent GTR, identification of prognostic factors influencing survival is urgently needed. Here we retrospectively analyzed prognostic factors for patients who underwent GTR of newly diagnosed GBM, with a particular focus on the influence of the subventricular zone (SVZ) as the tumor location...
January 22, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"